Skip to main content

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring


via The Scientist RSS https://ift.tt/Fze2Ipt Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab–interleukin 17A (IL-17A) drug-target complex. https://ift.tt/RXCpuDg July 21, 2022 at 09:47PM
Labels:

Comments

Post a Comment

Popular posts from this blog

Enhancing Cell Morphology-Based Analysis

via The Scientist RSS https://ift.tt/RkiFxGZ Learn how the latest AI-driven technology uses morphology to comprehensively analyze and sort cell populations. https://ift.tt/0hfk7tr August 03, 2023 at 10:19PM
Post a Comment
Read more

Accessible Lateral Flow Assays: Test to Treat, Test to Protect

via The Scientist RSS https://ift.tt/7aXpZQb From development to implementation, Rosanna Peeling discusses the importance of rapid tests for public health. https://ift.tt/xEQe8l9 October 18, 2023 at 08:30PM
Post a Comment
Read more

Engineered Bacteria Make Tumors More T Cell-Friendly

via The Scientist RSS https://ift.tt/Ku7FXvh Microbes designed to produce specific immunomodulatory metabolites could give immunotherapy a boost. https://ift.tt/xy2vXPZ April 08, 2022 at 08:41PM
Post a Comment
Read more